Literature DB >> 12044473

Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease.

T Bussière1, P D Friend, N Sadeghi, B Wicinski, G I Lin, C Bouras, P Giannakopoulos, N K Robakis, J H Morrison, D P Perl, P R Hof.   

Abstract

Although the presence of amyloid deposits is required to establish the neuropathologic diagnosis of Alzheimer's disease, from a clinical point of view, a direct contribution of these cerebral lesions to cognitive deficits is still controversial. The development and standardization of quantitative and accurate biochemical and neuropathologic methods may be critical to improve the postmortem diagnosis and clinicopathologic correlations. Here, we used a point counting method, based on the Cavalieri principle, to estimate the volume occupied by amyloid deposits in a discrete region of the prefrontal cortex and in the hippocampal formation, in brains from patients with cognitive status ranging from normal to severely demented. We demonstrate that the assessment of the total volume occupied by the amyloid deposits in the entorhinal cortex and subiculum can be considered an effective predictor of dementia severity. We also reveal the existence of a high degree of regional and interindividual heterogeneity in amyloid distribution and relative volume. Our data suggest that even though a correlation was observed between the stereologic point counting method and a non-stereologic random field thresholding approach, in most cases non-stereologic methods may not provide adequate samples of the tissue and may lead to unreliable estimates of amyloid burden due to the inhomogeneous distribution of amyloid in the cerebral cortex and the large variability among brains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044473     DOI: 10.1016/s0306-4522(02)00056-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  34 in total

1.  Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model.

Authors:  John F Reilly; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

Authors:  Mateen C Moghbel; Babak Saboury; Sandip Basu; Scott D Metzler; Drew A Torigian; Bengt Långström; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 3.  Single cell gene expression profiling in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  NeuroRx       Date:  2006-07

4.  Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau.

Authors:  Dara L Dickstein; Hannah Brautigam; Steven D Stockton; James Schmeidler; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-03-07       Impact factor: 3.270

Review 5.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

6.  Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein.

Authors:  Laibaik Park; Ping Zhou; Rose Pitstick; Carmen Capone; Josef Anrather; Erin H Norris; Linda Younkin; Steven Younkin; George Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-17       Impact factor: 11.205

Review 7.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

8.  Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.

Authors:  M N Sabbagh; K Cooper; J DeLange; J D Stoehr; K Thind; T Lahti; B Reisberg; L Sue; L Vedders; S R Fleming; T G Beach
Journal:  Curr Alzheimer Res       Date:  2010-06       Impact factor: 3.498

9.  Beta-amyloid burden is not associated with rates of brain atrophy.

Authors:  Keith A Josephs; Jennifer L Whitwell; Zeshan Ahmed; Maria M Shiung; Stephen D Weigand; David S Knopman; Bradley F Boeve; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson; Clifford R Jack
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

Review 10.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.